illumina strong growth continu
page full analyst note jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim oct
price data feb
rate updat feb
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
current hands-down leader genom sequenc illumina
face impress growth opportun emerg
technolog creat new research applic also
demand product sustain high earn
technolog advanc sequenc industri
brought cost assembl one genom nearli
billion year complet human genom project
almost matter day follow
announc illumina highseq earli
innov like recent launch novaseq continu push
cost enhanc access technolog
number sequenc whole human genom like
hundr thousand also see plenti opportun
increas demand especi oncolog reproduct health
estim genom sequenc market opportun exce
growth demand genom sequenc place
clear winner time
solid-phas amplif fluoresc label sequencing-by-synthesi
technolog support one versatil platform
cost turnaround time read length throughput error
rate -- squash current competit also offer
strong assort sampl prepar post-run data
analysi tool includ open-sourc cloud-bas data
storag genom assembl softwar
near term think continu leadership
threat disrupt technolog remain concern
on-going improv compani flow cell densiti
chemistri process camera speed support
throughput cost improv emerg
technolog made big promis unconvinc
emerg system dethron
meantim pursu innov method includ
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
major player life scienc tool analyz genet materi
revenu microarray genom sequenc machin
dispos make compani revenu approxim
compani sale come test servic essenti
growth stem compani genom sequenc product
includ compani high-throughput novaseq hiseq
instrument addit benchtop nextseq miseq miniseq
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
illumina strong growth continu jan
dont anticip chang fair valu estim
make adjust model
includ incorpor acquisit
forecast end year mostli
expect growth led growth
sequenc instrument growth sequenc
growth account stock effect
oper margin last year
overal still think remain well posit
sustain leadership genom sequenc market
leav narrow moat rate place
manag previous announc outlook
revenu growth match expect
growth forecast stem mid-single-digit instrument
growth sequenc consum growth
seem feasibl given ramp util
grow instal base machin on-going market
penetr genom sequenc includ oncolog
panel test non-invas prenat screen remain
strong tailwind addit upgrad
cycl newer high throughput novaseq product line
continu well even though shipment fell slightli
short manag expect least
placement year along launch
prime flow cell novaseq discount lower
throughput flowcel help push new current
benchtop custom onto higher throughput platform
lastli manag outlook adjust ep
slightli ahead current estim
rais fair valu estim
per share increas growth margin
forecast follow recent result think
maintain nearli averag revenu growth rate
next five year thank healthi demand sequenc
technolog despit concern competit
clinic diagnost market
assum sustain revenu growth
peer thank on-going strength research market
well grow adopt sequenc technolog
among clinic custom repres consider
global
macroeconom concern still anticip research
budget continu priorit genom sequenc
spend due research advanc technolog
opportun sinc sequenc potenti
disrupt segment older diagnost test addit
creat new test avenu liquid biopsi
screen test compani pursu
grail ventur cancer panel companion diagnost
opportun ultim pace growth market
constraint regulatori issu reimburs hurdl
among clinic custom base meanwhil expect
slower sale smaller microarray segment
invest new busi ventur like helix
reduc near-term profit despit
benefit rise higher-margin consum
instal base instrument despit higher research
develop spend ventur combin
increas salesforc requir clinic diagnost
market think opportun greater oper
leverag exist long term
product test come market clinic market
penetr increas project culmin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
benchtop market lead averag annual growth near
oper margin remain
manag difficulti scale
busi
competit increas price pressur recent ventur
lead higher on-going cost return capit remain
high-teen scenario
young compani emerg market
potenti disrupt technolog believ
rel high barrier entri rise switch cost
unmatch pace innov support
econom profit next decad even though risk
emerg technolog horizon largest
concern moat opinion current view
threat major disrupt technolog remot
current domin genom sequenc
market instrument versatil low oper cost
high throughput accuraci turnaround speed faster
simpler sampl prepar support data analysi
softwar make drive forc behind compani
market share market share nearli
grow base estim howev owe
compani essenti monopoli high-throughput
portion market sequenc genet
materi probabl come machin
face competit benchtop segment smaller
lab clinic applic thermo fisher
previous life technolog ion torrent platform
think barrier entri high genom sequenc
thank intersect three highli technic
instrument
complex data analysi -- requir read genet
inform ventur capit still easili flow
nascent market get actual product market
adjust oper margin averag return
invest capit estim illumina cost
equiti
give high uncertainti rate due
compani product concentr genom sequenc
market combin potenti disrupt entrant
highli technolog field
bull-cas scenario project faster market
adopt genom sequenc greater market share
gain less pressur compet sequenc
technolog support annual revenu growth
next sever year also assum less
competit greater oper leverag could boost
valu reach nearli scenario return
capit
fair valu approxim model slower
penetr genom sequenc technolog
competit emerg platform particularli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
prove extrem difficult numer contend
includ like sequenc techniqu nearli
alway emerg small-scal method develop
major research univers manufactur scalabl
develop molecular enzym need process
amplifi genet materi microfluid engin
complex softwar algorithm assembl massiv
amount data support custom servic creat
boost throughput along faster camera chemistri
process improv sequenc cycl time think
devic continu lead industri
sequenc cost speed throughput also
sampl prepar
technolog cloud-bas data storag
possess nearli issu pend patent
technolog
custom switch cost slowli rise
sequenc market opinion becom
wide adopt platform custom orient around
prepar method studi protocol clia
certif support industri
public difficult hurdl competitor quickli
overcom think factor becom even
import genom sequenc becom access
smaller research clinic laboratori possess less
technic expertis fewer resourc next
year food drug administr like becom
increasingli involv regul rise sequenc
technolog clinic diagnost market
requir evid accuraci reliabl back
publish research illumina miseq first
fda-approv genom sequenc instrument
market addit regulatori mileston come
near futur exampl manag discuss
agenc fda-approv oncolog panel specif
instrument manag plan enrol larg
clinic trial cancer screen test includ
grail ventur
imagin industry-lead innov
continu keep compani step ahead competitor
especi larger high-throughput market thank
addit advanc flow cell densiti read length
admit threat emerg sequenc
platform could derail trajectori think firm
domin high-throughput market expect
limit new technolog on-going
innov capit alloc preserv
compani growth opportun return capit due
high threshold competitor directli blunt illumina
essenti monopoli high-throughput portion
market dont envis threat segment
near futur sale high-throughput hiseq
machin compos nearli compani sale
estim think there risk
benchtop market base knowledg emerg
technolog skeptic competitor could
make seriou inroad next year
award stabl moat trend dont see
signific near-term threat exist platform
market nearli guarante illumina
leadership next year meanwhil illumina
continu research innov genom sequenc
launch iseq -- chip-bas detect machin --
exist platform continu struggl scale
platform inher technolog limit
give competit edg next year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oxford nanopor lead rel high error rate
compani face delay meet product
launch goal base cursori analysi limit
knowledg oxford technolog think compani
greater threat nich player like
time meanwhil instrument alreadi
push sequenc cost par initi rumor
oxford capabl base calcul illumina
initi investor oxford nanopor held
minor stake compani late
rest laurel unlik mani compani
announc technolog advanc
histori hold technolog develop close vest
announc new technolog readi
advanc industri difficult specul
continu aggress use capit resourc
pursuit improv exist technolog well
novel sequenc approach addit
earli investor oxford nanopor instanc
licens anoth nanopor technolog late
possibl simultan develop
in-hous nanopor devic time left
behind roch purchas early-stag nanopor
technolog acquisit strato genia
bio-rad purchas gnubio
roch recent announc discontinu
sequenc platform pyrosequenc technolog
struggl high error rate could keep pace
industri throughput addit seem thermo fisher
previous life technolog ion torrent platform
reach upper bound read densiti detect
limit chip technolog despit initi appeal
low reagent cost non-opt platform
meanwhil read length limit long run time
requir essenti render life technolog
thermo fisher previou solid platform obsolet
pacif bioscienc first success third-gener
whole molecul sequenc technolog probabl never
compet high-throughput platform like
carv small nich market platform
long read capabl help microbi
genom de novo analysi lack refer dna
awar multipl venture-back technolog -- rang
nanopor electron microscopi -- present low
extrem low probabl success view
current nanopor technolog view mani
next possibl evolut sequenc method thank
impress list promis includ littl sampl
prepar dna amplif need expens
reagent label long read length fast run time
greatli simplifi sequenc assembl data
analysi current oxford nanopor appear possibl
closest market technolog measur
charg differenti dna strand pass
nanopor best oxford first minion devic
minor competit threat benchtop instrument
segment opinion oxford potenti higher
throughput instrument would direct threat
seem potenti year away enter
market guess similar pacif bioscienc
real-tim process detect accuraci appear issu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market repres larg growth opportun
leapfrog platform lead market share
oweak econom condit constrain global
research budget academ govern
commerci market specif priorit
oa signific portion market growth
requir clinic adopt sequenc technolog
face consider regul valid
treatment guidelin reimburs challeng
current largest grow
instal base sequenc instrument
on-going sale higher-margin
futur success depend manag
abil sustain innov astut capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
think solid financi health thank
strong balanc sheet larg influx recur revenu
consum instal base sequenc
machin decemb possess nearli
billion cash invest compar
convert debt gross
debt/ebitda gener remain near time
although cash flow continu rise firm
like continu make invest includ modest
acquisit enhanc competit posit
adjust free
gener
gener revolv adjust
commit
give high uncertainti rate due
compani product concentr genom sequenc
market combin potenti disrupt entrant
highli technolog field disrupt technolog
new genom sequenc platform greatest risk
view outpac current
sequenc competitor market name roch
thermo fisher previous
pacif bioscienc ventur capit continu fund
could eventu
threaten leadership sequenc market
consider research develop shift
toward technolog could elimin need
time-consum sampl prepar camera laser
besid potenti lower-cost faster simpler
use third-gener technolog could also greatli
increas read length suggest easier align
sequenc less complic data manag
softwar program awar multipl ventur
develop new sequenc technolog current
state advanc difficult determin think
technolog earli phase develop
suggest littl threat near term
rapid pace
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
howev platform nanopor shown
potenti promis earli publish literatur numer
promis sequenc technolog fail
howev includ helico point
emerg technolog remain larg untest
like face numer develop challeng
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
assign exemplari stewardship rate
base compani histori shrewd capit alloc
manag face tall order quest sustain
blister pace
develop
field potenti disrupt
technolog one seriou misstep failur acquir
long-term success manag team
like cogniz threat anyon els
howev think excel drive industri
innov pick winner capit deploy
va collegeamerica gr fd amer
capit research manag compani
share
fund
share
fund
view innov high research
develop spend combin prescient
well-tim acquisit upheld impress growth
return capit domin sequenc
market larg stem acquisit solexa
gave foundat fluoresc
label termin sequencing-by-synthesi chemistri
sequenc machin persist leadership
push sequenc innov curv also
build sampl prep data analysi
posit prefer sequenc platform
nextbio moleculo address illumina
platform weak acquisit includ
bluegnom verinata health help lay
groundwork growth diagnost manag hope
recent busi ventur helix grail expand
market opportun genom test
franci desouza replac jay flatley ceo juli
desouza join compani presid
execut experi symantec addit cofound
number technolog compani despit recent
growth challeng late earli
leadership transit gone fairli smoothli flatley
ceo sinc transit role
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
execut chairman like continu
consider input strateg initi
flatley previous co-founder ceo molecular
dynam sale addit
board director john thompson --
board member sinc blain bowman
lead independ director follow retir
compens determin larg revenu
oper incom target perform stock unit
best measur valu creation view
minor quibbl relat compani histor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
life scienc diagnost industri offer attract
growth moat wari valuat
think plenti like life scienc
sever competit advantag lead econom
moat industri tend predict
attract growth outlook especi area
bioprocess analyt instrument genom
addit somewhat insul broader
macroeconom cycl nearli everi compani life
scienc diagnost manufactur coverag also earn
econom moat thank intang often pair
high switch cost valuat alreadi reflect
optim howev multipl across industri
look expens view current think water
agil becton dickinson reflect best
valu trade close territori view mettler
biomerieux significantli overvalu
moat common life scienc tool thank intang
switch cost gener award moat life
scienc diagnost firm record consist
innov larg instal base equip
dedic pull consum
chromatographi mass spectrometri market led
water agil creat one wide-moat
segment benefit low disrupt risk high
barrier entri comfort oligopoli razor-and-
blade busi model high custom switch cost
nich ga
outlook life scienc diagnost market
remain stabl attract pocket growth
estim market exce roughli billion grow
nearli annual depend market
segment popul growth increas drug research
volum workflow improv rise manufactur
qualiti standard emerg field genet research
test key industri growth driver
complet overview life scienc moat analysi
pleas see report life scienc diagnost industri
offer attract growth econom moat wari
valuat discuss growth outlook
econom moat life scienc industri
somewhat surpris announc
intend acquir billion cash
pacif give access smaller
nich long-read genom sequenc market come
odd time especi newer nanopor
technolog pose larger threat pacif busi
time dont expect chang fair valu
estim narrow moat rate seem confid
regul sign deal given differ
intend use instrument despit high
share overal genom sequenc instrument market
pacif also recent post slower growth
yet turn profit imagin expect new
product launch combin impress
innov record larg manufactur
market infrastructur improv pacif perform
unlik larger growth opportun clinic
market anticip pacif market potenti
remain research market accur long-read
data applic although deal look
expens nearli time trail sale manag
expect long-read market grow nearli
annual growth rate look roughli line
current forward revenu consensu pacif nearli
billion cash track billion oper
cash flow annual face roadblock fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
roadblock horizon oct
rais fair valu estim
per share compani perform top
bottom line surpass expect last
two quarter increas five-year annual
growth forecast almost although still think
share look expens admit compani growth
momentum market opportun remain attract
llumina tariff instrument sold china
custom countri prepurchas nearli million
consum quarter lead potenti
slight slowdown fourth quarter perform
see roadblock narrow-moat
leadership genom sequenc market manag
maintain revenu growth outlook year
rais adjust ep
post anoth strong quarter led
growth sequenc instrument consum
oper margin nearli basi point
novaseq placement uphold growth
manag continu note broad uptak across
custom categori includ nearli lower-
throughput miseq new-to-sequenc miniseq
custom besid on-going uptak
popul sequenc studi
anticip healthi demand sequenc technolog
clinic market persist thank improv insur
coverag averag risk prenat test liquid biopsi
oncolog panel rare genet disord newborn
children servic revenu continu perform
well growth meanwhil microarray sale grew
custom prepar influx consum
genet test holiday season
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
